JPWO2023095802A5 - - Google Patents
Info
- Publication number
- JPWO2023095802A5 JPWO2023095802A5 JP2023563705A JP2023563705A JPWO2023095802A5 JP WO2023095802 A5 JPWO2023095802 A5 JP WO2023095802A5 JP 2023563705 A JP2023563705 A JP 2023563705A JP 2023563705 A JP2023563705 A JP 2023563705A JP WO2023095802 A5 JPWO2023095802 A5 JP WO2023095802A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cells
- disease
- composition according
- cell population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190125 | 2021-11-24 | ||
| PCT/JP2022/043221 WO2023095802A1 (ja) | 2021-11-24 | 2022-11-22 | Ｔ細胞関連疾患を治療または予防するための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023095802A1 JPWO2023095802A1 (https=) | 2023-06-01 |
| JPWO2023095802A5 true JPWO2023095802A5 (https=) | 2025-10-29 |
Family
ID=86539431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563705A Pending JPWO2023095802A1 (https=) | 2021-11-24 | 2022-11-22 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250352578A1 (https=) |
| EP (1) | EP4438048A4 (https=) |
| JP (1) | JPWO2023095802A1 (https=) |
| KR (1) | KR20240130083A (https=) |
| CN (1) | CN118591379A (https=) |
| CA (1) | CA3238860A1 (https=) |
| MX (1) | MX2024006370A (https=) |
| TW (1) | TW202334397A (https=) |
| WO (1) | WO2023095802A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250018033A1 (en) * | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| JPWO2024204553A1 (https=) * | 2023-03-29 | 2024-10-03 | ||
| JP2025064863A (ja) * | 2023-10-06 | 2025-04-17 | 株式会社マイオリッジ | Ｔ細胞の培養方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047003A1 (en) * | 2007-10-12 | 2009-04-16 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Method and kit for rapid isolation of human foxp3+ treg cells |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EA027531B1 (ru) | 2011-09-13 | 2017-08-31 | Игорь Ронинсон | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
| RU2015107550A (ru) | 2012-08-23 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Новые фенилпиридин/пиразинамиды для лечения рака |
| WO2014063778A1 (en) | 2012-10-08 | 2014-05-01 | Merck Patent Gmbh | 2-aminopyridine compounds |
| GB201220157D0 (en) | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| HK1213544A1 (zh) | 2012-12-10 | 2016-07-08 | 霍夫曼-拉罗奇有限公司 | 新型二环苯基-吡啶/吡嗪用於治疗癌症 |
| WO2014106606A1 (en) | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| WO2014154723A1 (en) | 2013-03-29 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyrrole derivatives for the treatment of cancer |
| WO2014194245A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Ｃｄｋ８之醫療性抑制劑及其用途 |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2015144290A1 (en) | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| JP6521387B2 (ja) | 2014-04-18 | 2019-05-29 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP6529085B2 (ja) | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| CA3051469A1 (en) * | 2017-01-27 | 2018-08-02 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells derived from umbilical cord blood |
| CN114921468A (zh) | 2017-01-30 | 2022-08-19 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| US20210238551A1 (en) * | 2018-08-22 | 2021-08-05 | Osaka University | Method for Generating Regulatory T Cells |
| WO2020102321A1 (en) * | 2018-11-13 | 2020-05-22 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells with improved mitochondrial function |
| EP3891270A1 (en) * | 2018-12-07 | 2021-10-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
| MX2021013227A (es) * | 2019-04-30 | 2022-01-06 | Univ California | Expansion ex-vivo sin microesferas de celulas t reguladoras humanas. |
| US20210373951A1 (en) | 2020-05-28 | 2021-12-02 | Samsung Electronics Co., Ltd. | Systems and methods for composable coherent devices |
| US20250018033A1 (en) * | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| EP4532697A2 (en) * | 2022-06-03 | 2025-04-09 | Beam Therapeutics Inc. | Modified regulatory t cells and methods of using the same |
| EP4596684A1 (en) * | 2022-09-26 | 2025-08-06 | Regcell Co., Ltd. | Induced regulatory t cells containing chimeric antigen receptor (car) |
-
2022
- 2022-11-22 MX MX2024006370A patent/MX2024006370A/es unknown
- 2022-11-22 EP EP22898585.9A patent/EP4438048A4/en active Pending
- 2022-11-22 CA CA3238860A patent/CA3238860A1/en active Pending
- 2022-11-22 KR KR1020247020426A patent/KR20240130083A/ko active Pending
- 2022-11-22 JP JP2023563705A patent/JPWO2023095802A1/ja active Pending
- 2022-11-22 TW TW111144652A patent/TW202334397A/zh unknown
- 2022-11-22 CN CN202280077889.6A patent/CN118591379A/zh active Pending
- 2022-11-22 US US18/713,036 patent/US20250352578A1/en active Pending
- 2022-11-22 WO PCT/JP2022/043221 patent/WO2023095802A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023095802A5 (https=) | ||
| Martinez et al. | Can we cure hepatitis B virus with novel direct‐acting antivirals? | |
| Marsden et al. | Humanized mouse models for human immunodeficiency virus infection | |
| Ramírez-Valle et al. | Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17–driven responses | |
| Ren et al. | Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide | |
| Rivera et al. | Long-term regulated expression of growth hormone in mice after intramuscular gene transfer | |
| Yeilding et al. | Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives–an update | |
| JP2016204396A5 (https=) | ||
| Garaci et al. | Thymosin alpha 1: from bench to bedside | |
| Scherl et al. | Review of the safety and efficacy of ustekinumab | |
| Mendell et al. | 480. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes | |
| Bucala | Neuroimmunomodulation by macrophage migration inhibitory factor (MIF) | |
| Post et al. | Some effects of tritiated thymidine as a deoxyribonucleic acid label in the rat liver | |
| KR20240063969A (ko) | 클리스트리디움 곤디 포자와 펨브롤리주맙의 연합의 응용 | |
| JP2024000505A5 (https=) | ||
| Lu et al. | Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model | |
| CN118176301A (zh) | 含有与IFN-γ选择性结合的寡核苷酸的自身免疫性疾病治疗药物及该寡核苷酸 | |
| Pal et al. | Trained Innate Immunity | |
| Evensen | Kinetics of epidermal cell proliferation in experimental skin carcinogenesis | |
| CN111154712A (zh) | 一种Spexin促进胰岛素的分泌和胰岛细胞增殖的方法 | |
| CN1718731A (zh) | 一种hcv转基因小鼠模型及其构建方法与应用 | |
| Karlson | The combined use of Ethambutol (Dextro-2, 2′-[Ethylenediimino]-Di-l-Butanol) and Isoniazid in experimental tuberculosis of Guinea pigs | |
| Luo et al. | An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases | |
| Martin et al. | History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications | |
| WO2026037423A1 (zh) | IFN-γmRNA的反义寡核苷酸及其应用和药用组合物 |